Immunofluorescence (IF) and immunohistochemistry (IHC) analysis of the tumor sections exhibited that Oxa(IV)@ZnPc@M (+) dramatically enhanced CRT exposure and HMGB-1 release in vivo, obviously higher than Oxa and Oxa(IV)@ZnPc@M (Supplementary Fig. 23a, b), verifying the magnification of ICD-induction efficacy by targeted chemo-photodynamic therapy. Here, HMGB1 is linked to neoplasm.